RE:RE:RE:RE:Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A
July 24, 2024 - Amgen’s lupus pursuits have encountered another pitfall, this time via recently-purchased Horizon Therapeutics.
What may be a trip up for Horizon is also a gut punch for Amgen, in light of the fact that the California pharma’s lupus ambitions have yet to pan out. After the first quarter of the year, Amgen cut two lupus programs due to futility.
https://www.fiercebiotech.com/biotech/amgens-lupus-bets-continue-flounder-even-those-horizon
Amgen and Horizon agreed to their merger in December 2022. The deal, valued at $27.8 billion, was the largest biopharma M&A transaction struck last year, however they have agreed to delay the merger until December 2023 to work through the FTC actions against the merger.
https://www.fiercepharma.com/pharma/amid-ftc-wrangling-amgens-horizon-buyout-delayed-again-companies-now-seek-close-december